Biologics/Immunotherapy News

Peanut-coated microneedles may represent a safe and effective alternative to epicutaneous immunotherapy, according to a study published in Immunotherapy.

AstraZeneca has received an FDA complete response letter concerning its supplemental biologics license application for benralizumab for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.

PHOENIX — The Immune Epitope Database and Analysis Resource catalogs experimental data on antibody and T-cell epitopes in the context of infectious disease, allergy, autoimmunity and transplantation.

Researchers have associated a variant of the HLA-DPB1 gene with poor responsiveness to sublingual immunotherapy for Japanese cedar pollinosis, according to a study published in Allergy.

PHOENIX — Researchers identified predictive factors of grade 2 or worse reactions during peanut OIT in preschoolers, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

PHOENIX — With new treatments, technologies and billing policies, providers may feel like they are falling behind their competition and failing their patients and their practices. Strategies and resources, however, are available.

PHOENIX — Patients with H1 antihistamine-resistant chronic spontaneous urticaria experienced improvements with dupilumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

PHOENIX — Dupilumab significantly improved swallowing ability and reduced eosinophils in the esophagus, indicating histologic remission, compared with placebo, according to results from the phase 3 LIBERTY-EoE-TREET study.

House dust mite sublingual immunotherapy tablets reduced inhaled corticosteroid use among patients with mild to moderate allergic asthma, according to a systematic review in The Journal of Allergy and Clinical Immunology: In Practice.

David A. Khan, MD, FAAAAI, of University of Texas Southwestern Medical Center, will be installed as president of the American Academy of Allergy, Asthma & Immunology during its annual meeting Feb. 25 to 28 in Phoenix.